Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | P2RY1 | P47900 | 2/20 | 0.35 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.35 |
| ▸ | NPEPPS | P55786 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12570158 | 0.92 | HIF1A (0.37) | HIF1AP2RY1ENPP1NPEPPSPOLB | |
| SCHEMBL9913213 | 0.87 | NPEPPS (0.35) | HIF1ANPEPPSADORA2ALMNA | |
| SCHEMBL889648 | 0.87 | HIF1A (0.49) | HIF1AP2RY1ENPP1ADORA3POLB | |
| SCHEMBL9913204 | 0.86 | SLC29A1 (0.35) | HIF1AP2RY1ENPP1NPEPPSADORA1 | |
| SCHEMBL889554 | 0.83 | ADORA3 (0.42) | P2RY1ADORA3ADORA1ADORA2A | |
| SCHEMBL14788953 | 0.83 | ADORA3 (0.42) | P2RY1ADORA3ADORA1ADORA2A | |
| SCHEMBL12570156 | 0.83 | HIF1A (0.46) | HIF1AP2RY1ENPP1ADORA3POLB | |
| SCHEMBL889553 | 0.83 | SLC29A1 (0.37) | NPEPPS | |
| SCHEMBL889682 | 0.81 | HIF1A (0.59) | HIF1A | |
| SCHEMBL889581 | 0.80 | SLC29A1 (0.39) | NPEPPSADORA3ADORA1ADORA2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8969535-B2 | Photocleavable labeled nucleotides and nucleosides and methods for their use in DNA sequencing | LASERGEN, INC. (US) | 2015-03-03 | — | — | US | disclosed |
| US-20130072388-A1 | PHOTOCLEAVABLE LABELED NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN IN DNA SEQUENCING | AGILENT TECHNOLOGIES, INC. | 2013-03-21 | — | — | US | disclosed |
| US-8361727-B2 | 3′OH-unblocked, nucleotides and nucleosides base modified with labels and photocleavable, terminating groups and methods for their use in DNA sequencing | LASERGEN, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-20110287427-A1 | 3'OH-UNBLOCKED, NUCLEOTIDES AND NUCLEOSIDES BASE MODIFIED WITH LABELS AND PHOTOCLEAVABLE, TERMINATING GROUPS AND METHODS FOR THEIR USE IN DNA SEQUENCING | LASERGEN, INC. (US) | 2011-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072388-A1 | PHOTOCLEAVABLE LABELED NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN IN DNA SEQUENCING | UNG, NT5C3B, OGG1 | HIF1A 4666/4885P2RY1 793/4885ENPP1 154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.